202 related articles for article (PubMed ID: 32661298)
1. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
2. Combined histopathological risk score using TP53 protein expression, CD8
Chen W; Farchoukh L; Seigh L; Hartman DJ; Pai RK
Histopathology; 2021 Nov; 79(5):826-835. PubMed ID: 34121230
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy.
Rogers AC; Gibbons D; Hanly AM; Hyland JM; O'Connell PR; Winter DC; Sheahan K
Mod Pathol; 2014 Jan; 27(1):156-62. PubMed ID: 23887296
[TBL] [Abstract][Full Text] [Related]
5. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
6. [Changes in the CD8+ Density of Tumor Infiltrating Lymphocytes after Neoadjuvant Radiochemotherapy in Patients with Rectal Adenocarcinom].
Buka D; Dvořák J; Sitorová V; Hátlová J; Richter I; Sirák I
Klin Onkol; 2016; 29(3):204-9. PubMed ID: 27296405
[TBL] [Abstract][Full Text] [Related]
7. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment Mediators CD8
Zaghloul H; Abbas A; Abdulah D
J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
10. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
12. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
13. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
15. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
16. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
17. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
Shinto E; Omata J; Sikina A; Sekizawa A; Kajiwara Y; Hayashi K; Hashiguchi Y; Hase K; Ueno H
BJS Open; 2020 Apr; 4(2):301-309. PubMed ID: 32026629
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Budding and Tumor Microenvironment in Pretreatment Rectal Cancer Biopsies Predict the Response to Neoadjuvant Chemoradiotherapy.
Wen X; Zee SY; Shroyer KR; Bandovic J
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):1-7. PubMed ID: 34369419
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
[TBL] [Abstract][Full Text] [Related]
20. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Jäger T; Neureiter D; Fallaha M; Schredl P; Kiesslich T; Urbas R; Klieser E; Holzinger J; Sedlmayer F; Emmanuel K; Dinnewitzer A
Strahlenther Onkol; 2018 Nov; 194(11):991-1006. PubMed ID: 30069738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
